MARKET

XBI

XBI

SPDR® S&P Biotech ETF
NYSEARCA

Real-time Quotes | Provided by Morningstar

126.06
-0.43
-0.34%
After Hours: 126.06 0 0.00% 17:06 11/24 EST
OPEN
126.95
PREV CLOSE
126.49
HIGH
127.68
LOW
125.64
VOLUME
6.45K
TURNOVER
--
52 WEEK HIGH
127.81
52 WEEK LOW
62.94
TOTAL ASSET
5.33B
YTD YIELD
11.79%
1D
5D
1M
3M
1Y
5Y
News
Performance
Modernas COVID-19 vaccine candidate achieves 94.5% efficacy in late-stage trial, sparking market rally
Moderna Inc. said Monday its COVID-19 vaccine candidate met its primary endpoint in a Phase 3 trial, demonstrating 94.5% efficacy, a far higher benchmark...
MarketWatch · 11/16 13:18
Bond Exodus Vindicated After $1.2 Billion Flow From Treasury ETF
Bloomberg · 11/09 15:12
Novavax wins FDA fast track designation for COVID-19 vaccine candidate
Novavax Inc. undefined said Monday it has been granted U.S. Food and Drug Administration fast track designation for its COVID-19 vaccine candidate, a move...
MarketWatch · 11/09 13:40
FDA thumbs down on Biogen Alzheimer's candidate aducanumab
The FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted 8-1 (2 uncertain) that the Phase 3 EMERGE study (the one that was successful at the higher dose) evaluating
Seekingalpha · 11/06 20:27
Lipocine: TLANDO Might Become A Potential TRT Option In Patients With COVID-19 Infection
Lipocine is about to report data from its clinical study on whether TLANDO can restore testosterone levels in hypogonadal men without the dose titration requirement on November 9, 2020.Low baseline testosterone levels result in a higher risk of serious complications or even death in patients with COVID-19 infection.Testosterone replacement treatment using TLANDO might save plenty of lives of elderly men who are infected with COVID-19 infection.
Seekingalpha · 11/06 16:50
SPY Could Slump 8% in a Contested Election, Susquehanna Says
Bloomberg · 11/02 23:14
A $527 Billion Quant Giant Slashes Fees With Outflows Building
Quant giant Dimensional Fund Advisors is cutting management costs on more than a third of its mutual-fund offerings.
Bloomberg · 11/02 19:43
Junk-Bond ETF Suffers $3.7 Billion Exodus With Election Looming
In the final countdown before the U.S. presidential election, exchange-traded fund investors are pulling out of junk bonds.
Bloomberg · 11/02 16:19
More
No Data
Learn about the latest financial forecast of XBI. Analyze the recent business situations of SPDR® S&P Biotech ETF through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
Period
Return
Rank in Cat
1-Month
-6.5522%
--
3-Month
2.3267%
--
6-Month
18.1541%
--
1-Year
11.7862%
--
3-Year
8.0603%
--
5-Year
8.1538%
--
10-Year
19.4995%
--
Since Inception
13.9739%
--
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
Profile
Fund Name
SPDR® S&P Biotech ETF
Risk
Low risk
Inception Date
2006-01-31
Benchmark
NASDAQ Composite CR
Advisor Company
State Street Global Advisors Ltd
Custodian
State Street Bank & Trust Co
Manager
Feehily/Schneider/Donofrio